Inclusion Criteria
Type of Subject: Outpatient
boolean
12 years of age or older at Visit 1 (or 18 years of age or older if local regulations or regulatory status of study medication permit enrollment of adults only).
boolean
Male or eligible female. To be eligible for entry into the study, females or childbearing potential must commit to consistent and correct use of an acceptable method of birth control, as defined by the following: -Male partner who is sterile prior to the female subject entry into the study and is the sole sexual partner for that female subject -Implants of levonorgestrel or etonogestrel -Injectable progestogen -Oral contraceptive (either combined estrogen/progestin or progestin only) -Any intrauterine device (IUD) with a documented failure rate of less that 1% per year -Estrogenic vaginal ring -Double barrier method - spermacide + a mechanical barrier (e.g., a male condom or a female diaphragm) -Percutaneous contraceptive patches -Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse throughout the clinical trial and for a period after the trial to account for elimination of the drug (minimum of six days) -Female subjects should not be enrolled if they are pregnant, lactating or plan to become pregnant during the time of study participation. A serum pregnancy test is required for females of childbearing potential at the initial screening visit (Visit 1), Visit 5, Visit 7, Visit 10 and Visit13/Early Withdrawal. A urine pregnancy test will be performed at Visits 2 through 4, Visit 8 through 9, Visits 11 through 12 and the follow-up contact.
boolean
A diagnosis of asthma as defined by the NAtional Institutes of Health [NIH, 2007] at least 1 year prior to Visit 1.
boolean
A best FEV1 of 50% to 90% of the predicted normal value at Visit 1. NHANES III predicted values wil be used for subjects≥ 12 years of age [Hankinson, 1999]. If a subject is recorded as having Hispanic or Latino ethnicity, then Mexican-American equations will be used (irrespective of race). If a subject is recorded as being of African-American/African Heritage race, then the African American equations will be used. If a subject is recorded as being of Asian heritage race, then the Asian equations will be used. Otherwise the Caucasian equations will be used.
boolean
Demonstrated a ≥ 12% and ≥ 200 mL reversibility of FEV1 within 10 to 40 minutes following 2 to 4 inhalations of albuterol/salbitamol ihnalation aerosol (if required, spacers are permitted for reversibility testing only) or equivalent nebulized treatment with albuterol/salbutamol solution at screening.
boolean
Subjects must be using an approved dose of an ICS (as per specific prescribed information) for at least 12 weeks preceding Visit 1 and at a stable dose for at least 4 weeks preceding Visit 1. See List 1 for examples of allowed doses of commonly used ICS.
boolean
All subjects must have a history of one or more asthma exacerbations requiring treatment with oral/systemic corticosteroids or emergency department visit or in-patient hospitalization for the treatment of asthma within the previous 12 month. NOTE: subjects who have experienced an asthma exacerbation requiring oral/systemic corticosteroids in the 4 weeks prior to Visit 1 can not be enrolled in the study due to 4 week washout of the oral/systemic corticosteroids, but can enter Visit 1 once the washout period has been met.
boolean
All subjects must be able to replace short-acting beta2-agonists with albuterol/salbutamol inhalation aerosol at Visit 1 for use as needed for the duration of the study. Subjects must be able to withhold all ihaled short-acting beta-sympathomimetic bronchodilators for at least 6 hours prior to study visits.
boolean
All subjects must be able and willing to give written informed consent to take part in the study.
boolean
Dosage Lists
Asthma Therapy (Toltal Daily Dose (mcg/day)) 1=Ex-actuator dose 2=Ex-valve dose 3=Ex-mouth piece
integer
Asthma Therapy (Total Daily Dose (mcg/day))
integer
Exclusion Criteria
Defined for this protocol as an asthma episode that required intubation and/or associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 5 years
boolean
A subject must not have current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or respiratory abnormalities other than asthma.
boolean
A subject must not have any clinically significant, uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbated during the study.
boolean
A subject will not be elligible for the run-in if he/she has clinical visual evidence of oral candidiasis at Visit 1.
boolean
A subject must not have participated in a study (including a non-interventional study) or used any investigational drug (including devices) within 30 days prior to Vitis 1 or within ten half-lives (t1/2) of the prior investigational study (whichever is longer of the two).
boolean
Asubject may not have previously been randomized to treatment in a Phase III Fluticasone Furoate/GW642422 Inhalation Powder Study (i.e., HZA106825, HZA106827, HZA106829, HZA106839,HZA106851).
boolean
Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled or systemic cortocisteroid therapy. Known or suspected sensitivity to the constituents of the Novel Dry Powder Inhaler (i.e., lactose or magnesium stearate).
boolean
History of severe milk protein allergy.
boolean
A subject must not be using or require use of immunosuppressive medications during the study. NOTE: Immunitherapy for the treatment of allergies is allowed during the study provided it was initiated 4 weeks prior to Visit 1 and subjects remain in the maintenance phase for the duration of the study.
boolean
A subject will not be elligible if he/she or his/her parent or legal guardian has any infirmity, disability or geographical location which seems likely (in the opinion of the investigator) to impair complianca with any aspect of this study protocol or scheduled visits to the study center and non-compliance with study medication or procedures (i.e., completion of diary card).
boolean
it could interfere with the subjects proper completion of the protocol requirements.
boolean
Administration of any other prescription or over the counter medication which would significantly affect the course of asthma, or interact with sympathomimetic amines, such as: anticonvulsants (barbiturates, hydantoins, carbymazepine), polycyclic antidepressants, beta-adrenergic blocking agents (both cardio-selective and non-selective), phenothiasines, monoamines oxidase (MOA) inhibitors. Please refer to the SPM for further details.
boolean
A subject may not have used inhaled tobacco products within the past three month (i.e., cigarettes, cigars or pipe tobacco) or have historical use of 10 pack years or more (e.g., 20 cigarettes/day for 10 years).
boolean
A subject will not be eligible if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.
integer
A subject is not eligible if he/she is receiving a strong CYP 3A4 inhibitor within 4 weeks of Visit 1 (e.g., ritonavir, ketoconazole,itraconazole).
boolean
it includes but is not limited to the following:
integer